noribogaine
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 20, 2024 (NCT06480981)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Kappa opioid receptorAGONIST
Kappa opioid receptor agonist
- Serotonin transporterANTAGONIST
SLC6A4 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H]1C[C@H]2C[C@H]3c4[nH]c5ccc(O)cc5c4CCN(C2)[C@@H]13- Mol. weight
- 296.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068516 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06480981 | Phase 1 | Jun 20, 2024 | DemeRx IB, Inc., Richmond Pharmacology |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DemeRx IB, Inc. | For profit | 1 | 1 | 1 | 2024 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1